JPRN-UMIN000001817已完成2 期
Multicenter phase II study of FOLFIRI and bevacizumab as second-line treatment in advanced or recurrent colorectal cancer. - PROMETEUSII
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patient with contraindication to Irinotecan, 5-FU, l-LV, or Bevacizumab.
研究者
相似试验
已完成
2 期
Multicenter Phase II Study of FOLFIRI and biweekly Cetuximab combination chemotherapy as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer. ( FIRBIC )Colorectal CancerJPRN-UMIN000006819Kanagawa Cancer Center45
进行中（未招募）
1 期
Everest 2. A study for previously not treated patients with spread colorectal cancer characterized by the presence of wild non mutated K-Ras gene involving standard chemotherapy (FOLFIRI) and cetuximab either at standard or increased doses depending on the skin reactions determined by treatment.K-Ras wild type metastatic colorectal cancerMedDRA version: 16.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-009992-36-ATniversity Hospital Leuven130
进行中（未招募）
1 期
A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment of K-Ras wild type metastatic colorectal cancer: Everest 2 - Everest 2K-Ras wild type metastatic colorectal cancerMedDRA version: 12.1Level: LLTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2009-009992-36-BEniversity Hospital Leuven375
进行中（未招募）
1 期
Everest 2. A study for previously not treated patients with spread colorectal cancer characterized by the presence of wild non mutated K-Ras gene involving standard chemotherapy (FOLFIRI) and cetuximab either at standard or increased doses depending on the skin reactions determined by treatment.K-Ras wild type metastatic colorectal cancerMedDRA version: 13.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-009992-36-HUniversity Hospital Leuven108
进行中（未招募）
1 期
folfoxiri plus bevacizumab plus atezolizumab or folfoxiri plus bevacizumab nel carcinoma del colonretto metastatico.Metastatic Colorectal CancerMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2017-000977-35-ITG.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST201